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Abstract. The tumor immune microenvironment (TME) and 
immune checkpoints have been reported to serve a role in the 
pathogenesis of malignant mesothelioma (MM) and treatment 
outcome. Additionally, mismatch Repair (MMR) deficiency 
appears to enhance the response to checkpoints blockade in 
several tumors. The aim of the present study was to analyze 
programmed death-1 ligand 1 (PD-L1) expression in MM and 
to characterize the TME. This could help to understand the 
immune response, and evaluate its prognostic and predictive 
values. We also investigated MMR protein expression. We 
retrospectively analyzed 55 mesotheliomas to determine 
PD-L1, CD4+, CD8+, mutL homolog 1 (MLH1), mutS homolog 
2 (MSH2), mutS homolog 6 (MSH6) and PMS1 homolog 2, 
mismatch repair system component (PMS2) expression. We 
used an immunoscore (1+, 2+ and 3+) to evaluate tumor‑infil-
trating lymphocytes (TILs). TILs were observed in all but two 
samples (53/55); the majority had an immunoscore 1+ (30/53), 
while 2+/3+ was reported for 23/53 samples. A predominance 
of CD8+ was highlighted in 8 cases (15%). PD-L1 expres-
sion of ≥1% on tumor cells was displayed in 40 cases; in 9 
of these, ≥50% expression was reported. Of note, alterations 
in MMR staining was not observed. In addition, survival 
analysis revealed that epithelioid subtype was associated 
with better prognosis. We observed a trend towards poorer 
prognosis for ≥50% PD‑L1 expression on tumor cells, lower 
immunoscore (1+) and CD8+ TIL predominance. The present 
study highlighted the importance of exploring the TME and 
the standardization of PD-L1 assessment guidelines to apply 
in the field of immunotherapy. 
Introduction
Malignant mesothelioma (MM) is an aggressive and fatal 
tumor, frequently related to the prolonged exposure to asbestos. 
Although it is a rare disease, its incidence has been increasing 
in recent years due to the use of asbestos for many years in 
the past (1,2). Better survival is achieved with multimodal 
approaches, in particular when surgery, radiotherapy and 
chemotherapy (platinum compounds-pemetrexed) are used. 
Nevertheless, treatment has a moderate impact on survival; 
thus, novel therapeutic strategies are urgently required to 
improve prognosis, for example the use of immunotherapy (3). 
According to the recent pathological classification proposed 
by the World Health Organization, mesotheliomas can be 
divided into three main subtypes: Epithelioid, sarcomatoid and 
biphasic (4). Epithelioid MM is the most common subtype and 
has better prognosis, while the sarcomatoid one is the rarest 
type with the poorest prognosis (4). MM has been reported as an 
immunogenic tumor that induces infiltration of immune effector 
cells, regulatory T cells and cytokines (5,6); the immunological 
aspects of the disease require further investigation. 
Is well known that tumor immune microenvironment 
(TME) serves a major role in neoplastic progression, facili-
tating tumor cell evasion from adaptive immunity and T-cell 
checkpoint pathways (7). Among the factors implicated in 
immune response inhibition by tumor cells, programmed 
death-1 ligand 1 (PD-1) and its main ligand PD-L1 play a 
key role (7). PD-L1 acts as a negative regulator of T lympho-
cytes (8-10): It is expressed by T-cells, B cells, monocytes and 
several tumor‑infiltrating lymphocytes (TILs) and it has an 
important role in attenuating antitumor immune response. In 
addition, PD-L1 expression has been widely reported in several 
malignant tumors (11). Cancer cells expressing PD-L1 promote 
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the apoptosis of antigen‑specific human T‑cell clones (12) and 
inhibit CD4+ and CD8+ T-cell activation, thus decreasing 
the immune action against tumor cells (12). Immune check-
point inhibitors (ICIs) have already shown promising results 
in other tumors (13), and are also under investigation in MM 
in which the expression of PD-L1 has been detected, regard-
less of the predictive value in this neoplasia (3,14). ≥1% PD-L1 
expression is reported with different percentages in patients 
with MM (15-21), with higher positivity rates in non-epithelioid 
subtypes (18,19). 
Given the interaction between immune infiltrate and 
neoplastic cells, the characterization of TME could be of great 
value not only to understand the immune response, but also to 
determine its possible prognostic value. 
Additionally, the value of the combined immunoscore 
(PD-L1 expression in both tumor and immune cells) is 
increasing due to recent data in other tumor types (e.g. head and 
neck cancer). In particular the combined immunoscore seems 
to better predict efficacy to immunotherapy (22). Nevertheless, 
many studies into this field are lacking conclusive data (23). 
An important role in various malignancies is played by 
mismatch repair (MMR) genes, such as mutL homolog 1 
(MLH1), mutS homolog 2 (MSH2), mutS homolog 6 (MSH6) 
and PMS1 homolog 2, mismatch repair system component 
(PMS2). Some mismatch repair‑deficient tumors are sensitive 
to immune check point blockade, as of the increased number of 
neoantigens encoded by cancers, which enhance the anti-tumor 
response (24-26). Several studies have shown that the number 
of mutations in MMR genes correlates with the response to 
PD-1 blockade, providing further support for a relationship 
between mutational burden and treatment response (25,27). 
MMR‑deficiency may be considered in the identification of 
patients who may benefit from PD‑1 pathway blockade. 
MM has a lower tumor mutational burden when compared 
with other cancers (28); however, some patients may benefit 
from ICIs; this response may be related to the presence of 
immune cells in tumor microenvironment.
The aim of this retrospective study was to evaluate PD-L1 
expression in tumor cells and TILs in different histological 
subtypes of MM, and to characterize the immune microenvi-
ronment. MMR protein expression was been also investigated. 
Additionally, these parameters were evaluated in association 
with clinicopathological features to explore their possible 
prognostic value.
Materials and methods
Patient selection and samples. Fifty-eight consecu-
tive cases of MM were collected from January 2014 to 
December 2017 at the Division of Medical Oncology of 
Azienda Ospedaliero-Universitaria Policlinico of Modena. 
Out of the initial cohort, 55 surgical formalin-fixed and 
paraffin embedded specimens were available from the Unit of 
Pathology of Modena and were histologically identified with a 
light microscope as MM after staining with hematoxylin and 
eosin. The cases included 10 samples from females and 45 from 
males. The median age at diagnosis was 74 years old (range 
45-88 years). All the samples were obtained through surgical 
biopsies. The study was approved by the Ethical Committee of 
Azienda Ospedaliero-Universitaria of Modena (393/17).
Immunohistochemistry. All immunostainings were performed 
on the automated system Ventana BenchMark XT (Roche 
Diagnostics) (29) using the detection kit UltraView DAB; in 
the case of double staining for CD4 and CD8, the UltraView 
universal alkaline phosphatase red detection kit (Roche 
Diagnostics) according to the manufacturer's instructions. 
The following primary antibodies were used: Anti PD-L1 
(clone 22C3, cat. no. M3653, Dako; Agilent Technologies, 
Inc.) diluted 1:100, anti-human CD4 (cat. no. 790-4423) 
and anti-human CD8 (cat. no. 790-4460) for TILs (Roche 
Diagnostics), and antibodies against MLH1 (cat. no. 790-5091), 
MSH2 (cat. no. 790-5093), MSH6 (cat. no. 790-5092) and 
PMS2 (cat. no. 790-5094) for MMR-related protein expres-
sion (Roche Diagnostics) prediluted. The use of 22C3 PD-L1 
staining on Ventana's platform was supported by the assuring 
results reported in a recent paper (30). Positive controls were 
included in each staining run, human placenta for PD-L1, 
human tonsil for the immune markers, obtained from the 
Unit of Pathology of Modena. For MMR protein expression, 
a positive internal control was represented by non-neoplastic 
adjacent cells present in each slide. All sections were scored by 
two observers including one pathologist. PD-L1 expression was 
retained when tumor cells or TILs displayed a membranous 
staining, partial or complete of any intensity. The percentage 
of PD-L1 positive tumor cells relative to all viable tumor cells 
present in the specimen was recorded. PD-L1 positivity was 
defined as ≥1% of tumor cells or TILs staining by immuno-
histochemistry (31). Tissue sections were analyzed for the 
presence of tumor lymphocytic infiltration scored according 
to Marcq et al (15). Therefore, we analyzed the presence of 
lymphocytes and lymphoid aggregates (score 0=0 aggregates; 
score 1=1-5 aggregates; score 2=5-10 aggregates; score 3=>10 
aggregates) (15). A lymphoid aggregate was defined as ≥50 
lymphocytes clustered together (15). Then, cases were classi-
fied in negative when absence of tumor lymphocytic infiltration 
was observed; immunoscore 1+ (score 1); immunoscore 2+ 
(score 2); immunoscore 3+ (score 3). To analyze the CD4+ and 
CD8+ components, a percentage of expression of each marker 
was obtained via the evaluation of the total TILs.
Statistical analysis. Descriptive statistics of the study 
patients were reported. Continuous variables were expressed 
as mean, median, standard deviation and range, while 
categorical variables as absolute and percentage frequencies. 
Associations between categorical variables were assessed 
by means of Fisher exact tests. The Mann-Whitney test 
was performed to evaluate the relationship between PD-L1 
expression and histological subtype (epithelioid vs. others), 
stage at diagnosis, smoking history, professional asbestos 
exposure and gender. Overall survival times from diagnosis 
were graphically reported as Kaplan-Meier survival curves 
which were compared using a log-rank test. The survival 
analysis compared PD-L1 expression using different systems: 
In the first analysis, PD‑L1 expression evaluated on tumor 
cells, TILs, and on both cells types was stratified into <1, 
1-49 and ≥50%. In the second analysis, PD-1 expression 
was stratified into <50 and ≥50%, and in the third analysis 
into <1 and ≥1%. Comparisons between survival curves 
were expressed as hazard ratios (HR) with 95% confidence 
interval from a Cox regression model. Statistical analyses 
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were performed with R 3.4.3 (The R Foundation for statis-
tical computing, Wien). P<0.05 was considered to indicate a 
statistically significant difference.
Results
Patient population. Samples comprised 44 epithelioid, 
3 sarcomatoid, 7 biphasic and 1 desmoplastic tumors; 51 
involved the pleura and 4 the peritoneum. According to the 
American Joint Committee on Cancer (32), 18 tumors were 
of stage I, 13 of stage II, 15 of stage III and 5 of stage IV; for 
4 cases, the stage could not be evaluated. None of the patients 
received immunotherapy. The clinicopathological features of 
our MM series are summarized in Table I. 
Immune composition of MM tissue samples. TILs were 
observed in all but two samples (53/55). The majority of cases 
had an immunoscore 1+ (30/53), while an immunoscore 2+ or 
3+ was observed in 15/53 and 8/53 tissue samples, respectively. 
Tissue sections were stained for two immune cell markers. 
CD4+ and CD8+ TILs were present in all 53 samples. The 
CD8+/CD4+ ratio was calculated dividing the percentage of 
CD8 positive cells on CD4 positive cells; the predominance 
of CD8+ compared with CD4+ was defined as a ratio >1. A 
predominance of CD8+ expression was highlighted in 8 cases 
(15%). Representative examples of different immunoscore and 
CD4+ and CD8+ predominance are presented in Fig. 1.
PD‑L1 expression on tumor cells and TILs, and its 
association with tumor lymphocyte infiltration. The immu-
nohistochemical analysis for PD-L1, using a threshold of 
≥1% of tumor cells, showed membranous expression of 
PD-L1 in 40 tumors (73%) whereas 15 (27%) were negative 
(Fig. 2). According to Herbst et al (31), we added a third 
stratification variable considering PD‑L1 expression ≥50% 
of cells: Among the 40 positive cases, it was observed 
in 9 cases (5 epithelioid, 2 sarcomatoid, 1 biphasic and 1 
desmoplastic). In two of them (one biphasic and one epithe-
lioid), this high positivity was present both on tumor cells 
and on TILs. The expression of PD-L1 on TILs was detected 
in 32 cases (60%), of which two samples exhibited >50% 
of PD-L1 staining (Fig. 2). PD-L1 positivity was evaluated 
both on tumor cells and TILs. In 11 cases negative expres-
sion was detected in both cell types, while 28 cases were 
positive both on tumor cells and TILs. In 23 of these, the 
results were concordant with PD-L1 between 1-49% and in 
two samples with PD-L1 ≥50%; while in three cases PD-L1 
≥50% was found only on tumor cells (Table II). In 10 cases 
PD-L1 positivity was detected only on tumor cells, 7 with 
PD-L1 between 1-49% and 3 with ≥50% (Table II). On the 
contrary, in 4 cases, PD-L1 was positive only on TILs, yet to 
a low degree (1%) (Table II).
The association between PD-L1 expression and CD4+ or 
CD8+ predominance was reported in Table III (P=0.058). A 
predominance of CD4+ infiltrate was observed in the majority 
of tumors independently of PD-L1 expression. The correlation 
of PD-L1 and immunoscore is displayed in Table III. Higher 
immunoscore (2+/3+) was significantly associated to an inter-
mediate PD-L1 expression (1-49%) (P=0.019). Representative 
examples of PD-L1 immunostaining are shown in Fig. 1.
MMR protein expression. In all the analyzed MM samples, no 
alteration in MMR staining was found.
Association between PD‑L1 expression and clinicopathological 
features. ≥50% PD‑L1 expression on tumor cells was signifi-
cantly less common in the epithelioid subtype than in the other 
types (P=0.047). The absence of an association between PD-L1 
expression was found with smoking history, asbestos exposure 
and stage. Furthermore, the link between gender with immune 
checkpoints showed no statistically significant differences. The 
association with PD-L1 expression on tumor cells was evaluated 
with three systems: <1 and ≥1%; <1, 1‑49, ≥50; <50 and ≥50% 
(P=0.282; P=0.572; P=0.202). Also, the CD8+/CD4+ ratio 
(P=0.097) and immunoscore 2+/3+ vs. 1+ (P=0.164) exhibited 
no association with gender (data not shown). 
Association of PD‑L1 expression and tumor immune infiltrate 
with survival. After an average follow up of 14.4 months, 22 
(40.0%) patients were still alive; all but two had epithelioid 
mesothelioma, and the majority of them had PD-L1 expression 
<50%. The median overall survival time was 13.3 months. 
Median survival for patients for negative (<1%), moderate 
Table I. Clinicopathological features of mesothelioma patients.
Clinicopathological features Patients n=55
Age (mean ± SD, years) 73.7±8.2
  Median (range) 74 (43-88)
Sex
  Male 45 (82%)
  Female 10 (18%)
Histological subtype
  Epithelioid 44 (80%)
  Sarcomatoid 3 (5%)
  Biphasic 7 (13%)
  Desmoplastic 1 (2%)
Smoking history
  Never smoker 78 (14%)
  Current/former smoker 28 (51%)
  Unknown 19 (35%)
Professional asbestos exposure
  Yes 30 (55%)
  No 25 (45%)
Site
  Peritoneum 4 (7%)
  Pleural 51 (93%)
Stage
  I 18 (33%)
  II 13 (24%)
  III 15 (27%)
  IV 5 (9%)
  Unknown 4 (7%)
SD, standard deviation.
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(from 1-49%) and strong PD-L1 staining (≥50%) was 
13.0, 20.6 and 5.1 months, respectively. Median survival for 
epithelioid subtype was 17.3 months, while for other subtypes 
it was 5.9 months. According to the CD8+/CD4+ ratio, median 
survival in patients with CD8+ predominance was 3.3 months, 
while for CD4+ predominance was 17.3 months. Furthermore, 
patients with an immunoscore 1+ had 13.0 months of overall 
median survival, whereas it was equal to 20.6 months in 
patients with an immunoscore 2+/3+.
Survival curves based on the PD-L1 expression percentage 
(<1, 1‑49, ≥50%), histological subtype, CD4+ or CD8+ 
predominance (expressed as CD8+/CD4+ ratio; Table IV) and 
immunoscore (2+/3+ vs. 1+) are presented in Fig. 3 and HR 
values are listed in Table IV. Additionally, survival curves 
based on PD‑L1 expression on tumor cells (<1 and ≥1%) 
exhibited no statistically significant differences (Fig. S1).
Epithelioid subtype was associated with lower risk of death 
during the follow-up period (HR=0.42 95% CI=0.19-0.92; 
P=0.031). Moreover, we observed a trend toward a poorer 
prognosis for PD‑L1 expression on tumor cells ≥50%, lower 
immunoscore (1+) and CD8+ tumor‑infiltrating lymphocytes 
predominance. When we consider only two groups of PD-L1 
expression (<50 and ≥50%), the association with survival 
was more apparent; however, statistical significance was not 
observed (P=0.116). Furthermore, the association between 
PD‑L1 expression on TILs (P=0.906 for <1, 1‑49 and ≥50%; 
P=0.657 for <1 and ≥1%) and the combined expression on 
tumor cells and TILs (P=0.285) with survival were not 
statistically significant. 
As the extent of PD-L1 positivity was less observed in 
the epithelioid subtype, we applied the survival analysis 
only on these cases. Under these conditions, no statistically 
significant association was reported between PD‑L1 expres-
sion and survival (P=0.362 for <1, 1‑49 and ≥50%; P=0.974 
for <1 and ≥1%; P=0.168 for <50 and ≥50%). Additionally, 
CD8+/CD4+ ratio (P=0.474) and immunoscore 2+/3+ vs. 1+ 
(P=0.183) were not linked to survival.
Discussion
The present study aimed to evaluate PD-L1 expression on tumor 
cells and on TILs, to characterize the immune microenviron-
ment and investigate MMR protein expression in MM. We also 
explored the possible prognostic value of these parameters.
In our series of MM, PD-L1 expression on tumor cells 
was observed in 73% of cases using a cut‑off value of ≥1%. 
This finding is in accordance with several studies (13,16,17), 
Figure 2. Histogram of the cases characterized by PD-L1 expression 
on tumor cells and TILs. PD-L1, programmed death-1 ligand 1; TILs, 
tumor‑infiltrating lymphocytes.
Figure 1. TILs of malignant mesothelioma tissue samples. Staining 
with hematoxylin and eosin indicated the presence of lymphoid aggre-
gates. Immunoscore (A) 3+ and (B) 1+ (original magnification x100). 
Immunohistochemistry of PD-L1 expression on tumor cells and TILs. 
(C and D) Highly PD‑L1‑positive tumor cells ≥50%. The arrow in panel C 
indicates a lower positivity for PD‑L1 in TILs. Original magnifications x100 
and 400. The double immunohistochemical staining demonstrated the pres-
ence of lymphoid aggregates with CD4+ (brown) and CD8+ (red) lymphocytes. 
(E) Predominance of CD4+, original magnification x200; (F) Predominance 
of CD8+, original magnification x400. TILs, tumor‑infiltrating lymphocytes.
Table II. Combined expression of PD-L1 on TC and TILs.
 PD‑L1 ≥1% PD‑L1 <1%
 ------------------------------------------------------ -----------------------
Cells 1‑49% ≥50% 
TC and TILs 28/53 (54%)  11/53 (20%)   23/53  2/53; 3/53 (TC) 
TC only 10/53 (19%)   7/53 3/53 
TILs only 4/53 (7%)   4/53  
Number of all positive samples are shown. Expression of PD-L1 
using a threshold of ≥1% and stratified in two groups (1‑49% and 
≥50%) was evaluated. PD‑L1, programmed death‑1 ligand 1; 
TC, tumor cells; TILs, tumor‑infiltrating lymphocytes.
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which reported percentage from 54-68%, but differs from 
others (18-21), which revealed a lower percentage of posi-
tivity (from 20.7-41.8%). This is may be due to differences in 
sample size, antibodies and cut-off values, as well as patient 
heterogeneity among different studies. Of note, we reported 
an association between PD-L1 positivity and histotype. 
Furthermore, some studies have found lower PD-L1 expression 
in epithelioid subtype compared with other subtypes (15-18). 
PD-L1 on tumor cells was not always expressed simultane-
ously with PD-L1 on TILs as already reported (15,16,21) and 
in concordance with the findings in other tumor types (33).
PD-L1 expression has been correlated with worse prog-
nosis but better response to anti-PD-1 antibodies in many 
cancer types, such as NSCLC (34-37). In MM, several studies 
have demonstrated that PD-L1 tumor cells expression was an 
independent factor for worse overall survival (16,18-21). Our 
results showed that PD-L1 expression does not appear to be 
significantly associated with survival despite a trend toward 
a poorer prognosis with PD‑L1 expression in ≥50% on tumor 
cells. The absence of a significant association with survival is in 
agreement with two recent studies, in which a specific antibody 
(SP142) (38) and four different antibodies were employed (17). 
This finding was observed even when we compared survival 
with PD-L1 expression on TILs, and with the combined 
expression of tumor cells and TILs. Therefore, the value of 
PD-L1 requires further investigation and standardization of its 
assessment is needed to improve clinical practice. 
The predictive value of immunohistochemical screening 
concerning the response to anti-PD-L1 treatment for MM needs 
to be studied. Moreover, clinical practice may demand access to 
different PD‑L1 antibodies matched with specific staining plat-
forms and score criteria are required to apply a novel diagnostic 
tool. In addition, PD-L1 expression is a heterogeneous continuum 
in tumor cells that cannot be stated only as ‘present’ or ‘absent’. 
The identification of a cut‑off value for expression positivity 
based on immunohistochemistry remains a challenge at present. 
Also, the location of PD-L1 expression should be considered; it 
is presumed that membranous expression of PD-L1 may be the 
most relevant as PD-1 mediates downstream signaling cascades 
only when it has been ligated (39). Pathologists, oncologists and 
scientists should work together in order to develop guidelines to 
apply in this new field of cancer treatment. 
The role of the tumor immune microenvironment in 
neoplastic progression is supported by a large body of 
evidence (40). In our series of MM, we found in less than half 
of cases (23/53), a higher degree of lymphocytic infiltration 
(expressed as immunoscore 2+/3+) which was significantly 
associated to an intermediate level of PD-L1 expression. In 
the majority of cases (85%), immune cell infiltration was 
characterized by CD4+ predominance independently of PD-L1 
expression, while a predominance of CD8+ was detected only 
in 15% of mesotheliomas. Our data showed a trend toward 
a poorer prognosis with lower immunoscore (1+) and CD8+ 
TIL predominance. These findings are in line with recent 
literature data: CD4+ TILs are associated with better prog-
nosis; MM cases characterized by higher CD8+ T lymphocyte 
expression and a lower CD4/CD8-positive ratio achieve worse 
survival (13,16,20). In contrast, a favorable prognostic value of 
high levels of TILs in several tumors have been reported (41-43) 
and also in MM (44,45). However, as their true biological role 
in suppressing and promoting tumor growth is governed by a 
variety of positive and negative T-cell factors, as well as the 
PD/PD-L1 pathway, further investigation is needed.
Table III. Association between of PD-L1 expression on tumor cells and CD4+ or CD8+ predominance and immunoscore. 
 CD8+/CD4+ 
 --------------------------------------------------------------- Immunoscore
PD-L1 expression Number of Predominance  Predominance ----------------------------------------------
on tumor cells samplesa of CD8+ (%) of CD4+ (%) P-value 1+ (%) 2+/3+ (%) P-value
≥50% 8 3 (37.5) 5 (62.5) P=0.058b 5 (62.5) 3 (37.5) P=0.019b
1-49% 31 2 (6.5) 29 (93.5)  13 (41.9) 18 (58.1)
<1% 14 3 (21.4) 11 (78.6)  12 (85.7) 2 (14.3)
Total 53 8 (15.1) 45 (84.9)  30 (56.7) 23 (43.3)
aIn two cases of mesothelioma the immune infiltrate was not present. bAs determined by a Fisher's exact test. PD-L1, programmed death-1 
ligand. 
Table IV. Univariate analysis of pathological variables on 
overall survival.
 Univariate Cox analysis
 ---------------------------------------------------
Variables HR 95 CI% P-value
PD-L1 expression on tumor cells   
  ≥50 vs. <1% 1.58 0.57‑4.39 0.376
  1‑49 vs. <1% 0.70 0.32‑1.53 0.367
Histological subtype   
  Epithelioid vs. Other 0.42 0.19-0.92 0.19-0.92
CD8+/CD4+ Ratio   
  ≥1 vs. <1 1.96 0.68‑5.67 0.215
Immunoscore   
  2+/3+ vs. 1+ 0.76 0.37-1.60 0.476
CI, confidence interval; HR, hazard ratio; PD‑L1, programmed 
death-1 ligand.
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The role of MMR in the neoplastic process is well estab-
lished for several tumors (24). MMR-deficiency might be 
taken into consideration in order to identify those patients 
who may benefit from PD‑1 pathway blockade. Some studies 
have reported a contradictory relationship between mutational 
burden and treatment response (25,27), but further study 
is required. A recent report examined this in MM (46), and 
revealed a very low frequency (1.8%) of MMR deficiency. In 
our study, none of the examined MM samples presented loss of 
expression of the proteins codified by the four genes (MLH1, 
MSH2, MSH6 and PMS2). Taken together, these data suggest 
that the MMR pathway is less involved in the pathogenesis 
of mesothelioma. Other mechanisms should be investigated to 
understand the response to ICI.
In conclusion, in our series of 55 MM samples, we reported 
that the epithelioid subtype is an independent factor of better 
prognosis as previously reported in the literature. The other 
immunological parameters, including PD-L1, immunoscore 
and predominance of CD8+ TIL, were not significantly asso-
ciated with survival, although we observed a trend toward a 
poorer prognosis for increased PD-L1 expression on tumor 
cells, lower immunoscore (1+) and CD8+ TIL predominance. 
However, we highlight the importance of the tumor immune 
microenvironment and the standardization of immunohis-
tochemical techniques for PD-L1 assessment in order to 
obtain comparable results to improve understanding of the 
pathogenesis of this very aggressive neoplasia. 
We reported a case series in which the immunological 
parameters analyzed may provide insight into the prognostic 
aspects of the disease. Investigation should also be conducted 
in a clinical setting with patients receiving immunotherapy 
to validate the predictive value of these parameters. Firstly, it 
would be important for pathologists and oncologists to work 
together to develop homogeneous guidelines for this new field 
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